Alpha Teknova, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Lab Essentials at $9.2 million, 75% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
44
|
12
|
11
|
10
|
10
|
10
|
10
|
9
|
10
|
| Lab Essentials |
33
+9.5%
share 74.9%
|
9
+17.9%
share 75.4%
|
8
+3.4%
share 75.8%
|
7
+0.1%
share 68.4%
|
8
+16.0%
share 79.5%
|
8
share 75.7%
|
8
share 82.9%
|
7
share 73.6%
|
7
share 74.8%
|
| Clinical Solutions |
9
+27.9%
share 20.6%
|
2
+17.9%
share 19.9%
|
2
+84.6%
share 19.4%
|
3
+47.1%
share 27.3%
|
2
-13.1%
share 16.3%
|
2
share 20.0%
|
1
share 11.9%
|
2
share 20.0%
|
2
share 20.5%
|
| Other Product |
2
-0.7%
share 4.5%
|
1
+31.7%
share 4.7%
|
1
+4.1%
share 4.8%
|
0
-27.1%
share 4.4%
|
0
-2.4%
share 4.2%
|
0
share 4.2%
|
1
share 5.3%
|
1
share 6.4%
|
0
share 4.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- TKNO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hollister, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1850902
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.